Skip to main content

PD-MitoQUANT – A quantitative approach towards the characterisation of mitochondrial dysfunction in Parkinson's disease

Objective

Mitochondrial dysfunction is implicated in Parkinson’s Disease (PD), but detailed understanding of the cause and effect in αSyn toxicity is lacking. Through provision of quantitative and systematic characterisation of mitochondrial dysfunction, PD-MitoQUANT will provide unprecedented understanding of the role of mitochondrial dysfunction in PD, identify and validate novel disease biomarkers, and propose innovative therapeutic targets that can be further progressed by the EFPIA partners. The consortium leverages multi-disciplinary expertise in the fields of αSyn biochemistry, iPSC-derived PD models, mitochondrial function and structural analysis, proteotoxicity, ER stress and UPR signaling, systems biology of mitochondrial function, and in vivo animal models. A key focus will be quantitative description and integrated analysis of mitochondrial function and its relation to proteotoxicity; representing a key panel of consortium partners Prehn [RCSI], Abramov [UCL], Corti [ICM] and Koopmann [RUMC] who also have assembled long–standing expertise in primary neuron culture, iPSC-derived neurons, PD in vivo models, proteostasis and ageing studies. These investigations will be supported by expert teams in iPSC-derived in vitro PD models and in vivo PD models from the academic partners (Hunot [ICM], Melki [CNRS], Di Monte [DZNE], Broccoli [CNR], SME [Mimetas] and EFPIA partners [Teva], [Lundbeck] and [UCB]. Through integrated in vitro, in silico and in vivo approaches, and supported computationally by SME [GENEXPLAIN], PD-MitoQUANT will perform thorough and unprecedented investigations of mitochondrial dysfunction. Finally, the consortium will initiate a European research platform of excellence investigating mitochondrial dysfunction in PD continuing beyond the project, further supported by [PUK]’s PD human tissue biobank. This will provide long-term and sustainable progress in the understanding of mitochondrial dysfunction in PD and towards clinical application.

Field of science

  • /medical and health sciences/basic medicine/neurology/parkinson
  • /natural sciences/biological sciences/biochemistry

Call for proposal

H2020-JTI-IMI2-2017-13-two-stage
See other projects for this call

Funding Scheme

IMI2-RIA - Research and Innovation action

Coordinator

ROYAL COLLEGE OF SURGEONS IN IRELAND
Address
Saint Stephen's Green 123
2 Dublin
Ireland
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 095 123,75

Participants (13)

INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE
France
EU contribution
€ 855 375
Address
Boulevard De L'hopital 47
75013 Paris
Activity type
Research Organisations
DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN EV
Germany
EU contribution
€ 541 118,75
Address
Sigmund Freud Strasse 27
53127 Bonn
Activity type
Research Organisations
CONSIGLIO NAZIONALE DELLE RICERCHE
Italy
EU contribution
€ 544 635
Address
Piazzale Aldo Moro 7
00185 Roma
Activity type
Research Organisations
UNIVERSITY COLLEGE LONDON
United Kingdom
EU contribution
€ 360 587,50
Address
Gower Street
WC1E 6BT London
Activity type
Higher or Secondary Education Establishments
STICHTING KATHOLIEKE UNIVERSITEIT
Netherlands
EU contribution
€ 403 885
Address
Geert Grooteplein Noord 9
6525 EZ Nijmegen
Activity type
Higher or Secondary Education Establishments
GENEXPLAIN GMBH
Germany
EU contribution
€ 148 875
Address
Am Exer 19 B
38302 Wolfenbuttel
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
MIMETAS BV
Netherlands
EU contribution
€ 250 835
Address
Jh Oortweg 19
2333CH Leiden
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
France
EU contribution
€ 160 000
Address
Rue Michel Ange 3
75794 Paris
Activity type
Research Organisations
PINTAIL LTD
Ireland
EU contribution
€ 137 500
Address
Springhill Avenue 77
A94 K542 Blackrock
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Israel
EU contribution
€ 0
Address
5 Basel St
49131 Petach Tivka
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
H. LUNDBECK AS
Denmark
EU contribution
€ 0
Address
Ottiliavej 7-9
2500 Valby
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UCB BIOPHARMA SRL
Belgium
EU contribution
€ 0
Address
Allee De La Recherche 60
1070 Bruxelles
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
PARKINSON'S DISEASE SOCIETY OF THEUNITED KINGDOM LBG
United Kingdom
EU contribution
€ 0
Address
Vauxhall Bridge Raod 215
SW1V 1EJ London
Activity type
Other